While no ART class has been shown to reduce the risk of KS specifically, more potent ART, with better safety profiles, will likely lead to more rapid CD4-T cell count recovery, faster decline in HIV viral load, and better HIV treatment adherence, which would contribute to further reductions in the incidence of HIV-associated KS. The gene discussed is CD4; the disease is Kaposi's sarcoma.